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Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to 
Gemcitabine Resistance in Pancreatic Cancer 
Bing Song1, X. Shawn Liu2, Steven J. Rice1, Shihuan Kuang3,6, Bennett D. Elzey4,6, Stephen F. Konieczny1,6, 
Timothy L. Ratliff4,6, Tony Hazbun5,6, Elena G. Chiorean7, and Xiaoqi Liu2,5 
Abstract 
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all 
patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the 
mediator of gemcitabine resistance, but the molecular mechanism remains unknown. In this study, we show 
that Plk1 phosphorylation of Orc2 and Hbo1 mediates the resistance to gemcitabine. We show that the level of 
Plk1 expression positively correlates with gemcitabine resistance, both in pancreatic cancer cells and xenograft 
tumors. Overexpression of Plk1 increases gemcitabine resistance, while inhibition of Plk1 sensitizes pancreatic 
cancer cells to gemcitabine treatment. To validate our findings, we show that inhibition of Plk1 sensitizes 
tumors to gemcitabine treatment in a mouse xenograft study. Mechanistically, we find that Plk1 phosphor-
ylation of Orc2 maintains DNA replication on gemcitabine treatment. Furthermore, Plk1 phosphorylation of 
Hbo1 transcriptionally increases cFos expression and consequently elevates its target multidrug resistance 1 
(MDR1), which was previously reported to confer chemotherapeutic drug resistance. Knockdown of cFos or 
MDR1 sensitizes gemcitabine-resistant cells to gemcitabine treatment. Finally, pancreatic cancer cells expres-
sing Plk1-unphosphorylatable mutants of Orc2 or Hbo1 are more sensitive to gemcitabine than cells expressing 
wild-type Orc2 or Hbo1. In short, our study provides a mechanism for Plk1-mediated gemcitabine resistance, 
suggesting that Plk1 is a promising target for treatment of gemcitabine-resistant pancreatic cancer. Mol Cancer 
Ther; 12(1); 58–68. 2012 AACR. 
Introduction 
The pancreas is a unique organ that has both exocrine 
and endocrine compartments. Pancreatic cancer is the 
fourth leading cause of cancer-related death in the United 
States, with a 5-year survival rate of less than 6%. More 
than 90% of pancreatic cancers arise from the exocrine 
portion of the pancreas and are pancreatic ductal adeno-
carcinomas. Because of a lack of early cancer-related 
symptoms, patients with pancreatic cancer are often diag-
nosed at an advanced stage (1, 2). 
Gemcitabine, a deoxycytidine analogue, is the standard 
chemotherapy treatment for advanced pancreatic cancer. 
Gemcitabine can directly incorporate into DNA or inhibit 
ribonucleotide reductase to prevent DNA replication and, 
thus, tumor cell growth (3). However, almost all patients 
have either primary or eventually gain secondary resistance 
to gemcitabine treatment. The major causes for resistance 
can be summarized into 3 aspects: failure of gemcitabine 
uptake through hENT1 transporter, decrease of effective 
drug dose by enzyme metabolism, and gain of resistance to 
cellular stresses or apoptosis. Because of potential im-
proved cytotoxicity, several combination therapies of gem-
citabine plus additional agents are being tested in clinical 
trials. So far, gemcitabine with erlotinib, an epidermal 
growth factor receptor tyrosine kinase inhibitor, is the only 
U.S. Food and Drug Administration-approved combina-
tion treatment. This regimen has a modest effect, which can 
prolong median overall survival for less than 2 weeks (4). 
Thus, understanding the molecular events that occur dur-
ing the development of gemcitabine resistance will lead to 
improvement of pancreatic cancer treatments. 
Polo-like kinase 1 (Plk1) is a well-studied serine and 
threonine protein kinase. It plays important roles in cell 
proliferation, such as mitotic entry, centrosome matura-
tion, kinetochore-microtubule attachment, chromosome 
segregation, and cellular checkpoint adaptation (5–12). 
Although evidence of Plk1 as an oncogene is scarce, it is 
overexpressed in various tumors. In addition, the level 
of Plk1 correlates with poor prognosis of cancer patients 
(13). Inhibition of Plk1 induces mitotic arrest, followed by 
cell death in cancer cells, but not in normal cells (14). A 
recent study suggests that Plk1 might be a mediator for 
gemcitabine resistance in pancreatic cancer. Among 
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approximately 40 potential target genes, Plk1 was the only 
gene that distinguished gemcitabine-sensitive versus 
-resistant tumors (15). Our previous work indicates that 
Plk1 phosphorylates origin recognition complex 2 (Orc2) 
to promote DNA replication under replication stress such 
as the one induced by gemcitabine treatment (16). We also 
reported that Plk1 regulates prereplicative complex (pre-
RC) formation through phosphorylation of histone acet-
yltransferase binding to the Orc1 (Hbo1; ref. 17). Therefore, 
we hypothesize that Plk1-associated kinase activity 
toward Orc2 and Hbo1 drives DNA replication in the 
presence of gemcitabine, eventually contributing to devel-
opment of gemcitabine resistance in pancreatic cancer. 
To test our central hypothesis, we first investigated the 
correlation between Plk1 expression and gemcitabine 
resistance with a combination of different pancreatic cell 
lines, xenograft mice and pancreatic cancer patient tis-
sues. Our data suggest that Plk1 overexpression correlates 
with gemcitabine resistance in pancreatic cancer cells and 
xenograft tumors. Inhibition of Plk1 activity significantly 
enhances the antitumor effect of gemcitabine in a Panc-1 
xenograft model. Mechanistically, we found that Plk1 
phosphorylation of Orc2 at the origin of DNA replication 
is increased on gemcitabine treatment, and that cells 
expressing a Plk1-unphosphorylatable mutant of Orc2 
are more sensitive to gemcitabine treatment. Surprisingly, 
gemcitabine treatment decreases Hbo1 at the replication 
origin but recruits it to the promoter of cFos, an AP-1 
transcription factor. We further show that Hbo1 phos-
phorylation by Plk1 upregulates the transcriptional 
expression of cFos, consequently resulting in an elevation 
of its target multidrug resistance 1 (MDR1). Knockdown 
of cFos or MDR1 sensitizes gemcitabine-resistant cells to 
gemcitabine treatment. Taken together, our findings 
define an important signaling pathway of gemcitabine 
resistance in pancreatic cancer, suggesting a novel strat-
egy to treat gemcitabine-resistant pancreatic cancer. 
Materials and Methods 
Chemicals 
BI2536 was purchased from Symansis NZ Ltd, New 
Zealand. Gemcitabine (Cat. 3259) was purchased from 
Tocris Bioscience (Fig. 2B and C). 
Mouse xenograft model 
Panc-1 cells (5 106 cells per mouse) were mixed with 
an equal volume of Matrigel (Collaborative Biomedical 
Products) and inoculated into the right flank of athymic 
nude mice (Harlan Laboratories). One week later, the 
animals were randomized into treatment and control 
groups of 5 mice each. BI2536 was dissolved in 0.1 N HCl, 
diluted with 0.9% NaCl, and injected into the tail vein 
twice weekly for 6 weeks. Gemcitabine was dissolved in 
0.9% NaCl, diluted with 0.9% NaCl, and injected into the 
tail vein twice weekly for 6 weeks. Tumor volumes, 
W2 3estimated from the formula: V ¼ L /2 (V, mm  ; L, 
mm; W, mm), were measured on alternate days with 
digital calipers. 
Statistical analysis 
A standard 2-tailed unpaired Student t test was 
used to calculate differences between samples. One-
way ANOVA was used to determine statistically sig-
nificant differences from the mean in the xenograft 
study. 
Cell culture, transfection, and RNAi 
The Panc-1 and BxPC-3 cells were purchased from the 
American Type Culture Collection. Cells were initially 
grown and multiple aliquots were stored at 180 C for 
future use as required. Cells were purchased more than 6 
months ago and were not further tested or authenticated 
by the authors. Panc-1 cells were cultured in Dulbecco’s 
Modified Eagle Medium supplemented with 10% FBS, 
100 units/mL penicillin, and 100 units/mL streptomycin 
at 37 C in 5% CO2. BxPC-3 cells were cultured in 
RPMI1640 medium. HPDE6 cells were cultured in kera-
tinocyte medium (Invitrogen). Plasmid DNA was trans-
fected with MegaTran (Origene) as described by the 
manufacturer. The cFos (sc-29221) and MDR1 (sc-29395) 
siRNAs were purchased from Santa Cruz Biotechnology 
and transfected with Oligofectamine (Invitrogen) as 
described by the manufacturer. 
Western blotting 
After cells were lysed in AMI lysis buffer (Active 
Motif), proteins were detected by Western blotting with 
antibodies against Plk1 (sc-17783; Santa Cruz Biotech-
nology), b-actin (A5441; Sigma), and PARP (AB3565; 
Millipore). 
Immunohistochemistry 
After murine or human paraffin-embedded slides were 
deparaffinized and rehydrated, antigens were retrieved in 
antigen unmasking solution (Vector Laboratories) with a 
2100-Retriever (PickCell Laboratories). Samples were 
then incubated with primary antibodies against Plk1 
(08544; Upstate) and Ki-67 (ab16667; Abcam) or subjected 
to TUNEL assay (11684817910; Roche). 
Cell viability assay 
Cells were grown in 96-well plates, and viable cell 
numbers were determined with the CellTiter-Glo Lumi-
nescent Cell Viability Assay kit (Promega) as described by 
the manufacturer. 
Combination index 
IC50 and combination index of gemcitabine and BI2536 
were calculated as indicated in (18). Combination index 
more than 1 indicates antagonism; combination index less 
than 1 indicates synergy; and combination index equal to 1 
indicates an additive effect. 
BrdU labeling assay 
BrdU-labeling assays were conducted with a kit from 
Roche (Cat.11170376001) according to the manufacturer’s 
instructions. 
www.aacrjournals.org Mol Cancer Ther; 12(1) January 2013 59 
Downloaded from mct.aacrjournals.org on August 30, 2021. © 2013 American Association for Cancer Research. 
Published OnlineFirst November 27, 2012; DOI: 10.1158/1535-7163.MCT-12-0632 
Song et al. 
TUNEL assay 
TUNEL assays were conducted with a kit from Roche 
(Cat.11684817910) according to the manufacturer’s 
instructions. Details of isolation of cells from xenograft 
tumors, chromatin immunoprecipitation (ChIP), and 
quantitative real-time PCR (qRT-PCR) analysis are 
described in supplementary material. 
Results 
Plk1 is overexpressed in pancreatic tumors 
To follow the expression of Plk1 protein in pancreatic 
ductal adenocarcinoma, we conducted immunohisto-
chemical (IHC) staining of Plk1 on a pancreatic tissue 
microarray (n ¼ 140) that included normal pancreas, 
cancer-adjacent tissue, and pancreatic ductal adenocarci-
noma. We found that nearly 80% of the tumors had 
positive Plk1 staining (60% with strong staining and 
20% with weak staining), while only 20% of the cancer-
adjacent tissue had positive Plk1 staining, and 80% to 90% 
of normal tissues had no Plk1 staining (Fig. 1). The 
difference of Plk1 protein expression between normal and 
cancer tissues is statistically significant. Taken together, 
these data suggest that Plk1 is significantly differently 
expressed between normal and cancerous tissue. 
Plk1 expression correlates with gemcitabine 
resistance in vitro and in vivo 
To investigate whether the elevated Plk1 protein 
levels in pancreatic tumor samples correlates with an 
active role of Plk1 in gemcitabine resistance of pancre-
atic cancer, we measured the IC50 values of gemcitabine 
in 4 different pancreatic cell lines, HPDE6 (an immor-
talized human pancreatic epithelial cell line), BxPC-3 
(human pancreatic cancer cell line), Panc-1 (human 
pancreatic cancer cell line), and AsPC-1 (human pan-
creatic cancer cell line). HPDE6 and BxPC-3 had low 
IC50 values, thus representing gemcitabine-sensitive  
cell ines, while Panc-1 and AsPC-1 cells had high IC50 
values, thus possessing the gemcitabine-resistant pro-
perty (Supplementary Table S1). To compare Plk1 levels 
in cell lines with different gemcitabine sensitivities and 
to avoid the possibility of comparing cells at different 
cell cycle stages or with different proliferation rates, we 
synchronized the cells at S phase with thymidine or at M 
phase with nocodazole, followed by Western blotting. 
Within the same stage of the cell cycle, Panc-1 cells had 
the most abundant Plk1 protein, while HPDE6 cells 
had the lowest level of (Fig. 2A), positively correlating 
with the gemcitabine IC50 values of these cell lines 
(Supplementary Table S1). 
To determine whether the sensitivity to gemcitabine is 
influenced by Plk1 activity, we measured the combination 
index of gemcitabine and BI2536 (an ATP competitive 
inhibitor that specifically inhibits Plk1 kinase activity) as 
described in the materials and methods section (Fig. 2B 
and C). The IC50 value of gemcitabine for Panc-1 cells was 
1284 nmol/L (Table 1). However, the IC50 of gemcitabine 
was reduced to 44 nmol/L when the cells were treated in 
combination with 2 nmol/L BI2536. The combination 
index was calculated to be 0.3 (Table 1), which is less than 
1, suggesting a synergistic effect between gemcitabine and 
BI2536. 
Because Panc-1 cells have the highest Plk1 level and are 
most resistant to gemcitabine, we treated Panc-1 cells with 
gemcitabine, BI2536 alone, or gemcitabine in combination 
with BI2536. We followed cell death by Western blot of 
cleaved-PARP protein. PARP is a poly ADP-ribose poly-
merase that facilitates the survival of cells. Cleavage of 
PARP disassembles cellular structure and serves as a 
marker for cellular apoptosis. Gemcitabine or BI2536 
alone had a minimal effect on cell death, but inhibition 
of Plk1 activity by BI2536 enhanced gemcitabine-induced 
cellular apoptosis (Fig. 2D). Consistent with the result 
in Fig 2D, the combination of gemcitabine and BI2536 
led to significantly reduced cell survival compared with 
gemcitabine or BI2536 alone (Supplementary Fig. S1A), 
indicating that inhibition of Plk1 sensitizes gemcitabine-
resistant cells to the chemotherapy. To further expand 
our observation, we also repeated this experiment in 
AsPC-1 cells, which is a gemcitabine-resistant cell line, 
and detected similar enhanced cellular apoptosis by inhi-
bition of Plk1 activity using BI2536 in the presence of 
gemcitabine (Supplementary Fig. S1C and D). To confirm 
this observation, we overexpressed Plk1 in HPDE6 cells, 
which have the lowest Plk1 protein level. Plk1 overex-
pression induced gemcitabine resistance as shown by a 
decreased cleaved-PARP protein level compared with 
control samples (Fig. 2E). In conclusion, the level of Plk1 
protein influences responsiveness to gemcitabine treat-
ment in pancreatic cells. 
With the aim to better assess the correlation between 
Plk1 protein expression and gemcitabine sensitivity, 
we examined the Plk1 protein level in xenograft tu-
mors. Briefly, animals bearing subcutaneous pancreatic 
tumors derived from Panc-1 cells were treated with 
40 mg/kg gemcitabine. After 8 weeks of treatment, the 
tumors showed different responses to gemcitabine. 
We repeated this experiment for several times, and 
observed a similar trend that the Plk1 protein expres-
sion level is relatively lower in tumors with smaller 
volume, indicating that these tumors are more sensitive 
to gemcitabine treatment (Fig. 2F–I). Cyclin A protein 
levels in these tumors are similar, suggesting that Plk1 
protein expression levels were compared in tumor cells 
with a similar cell-cycle distribution. Two substrates of 
Plk1 that might be involved in Plk1-mediated gemcita-
bine resistance were also measured. Neither Orc2 nor 
Hbo1 protein levels show any obvious differences 
among these tumors; therefore, it is unlikely that gem-
citabine resistance is more related to the protein levels 
of the Orc2 and Hbo1 (Fig. 2I). More importantly, to 
assess the significance of this correlation, we quantified 
the Plk1 protein levels (Fig. 2I) and measured the cor-
relation efficiency between Plk1 expression signal inten-
sity and tumor volume by Pearson product-moment 
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Figure 1. Plk1 is overexpressed in pancreatic cancer tissues. A, representative images of immunohistochemical staining of a pancreatic cancer tissue 
microarray with an anti-Plk1 antibody. This tissue microarray includes pancreatic adenocarcinomas, cancer adjacent tissues, and normal pancreatic 
tissues. B, a representative image of Plk1 immunohistochemical staining of normal pancreatic tissue. C, a representative image of weak Plk1 
immunohistochemical staining of pancreatic adenocarcinoma tissue. D, a representative image of strong Plk1 immunohistochemical staining of pancreatic 
adenocarcinoma tissue. E, quantification of Plk1 immunohistochemical staining in the pancreatic cancer tissue microarray. (The difference between 
normal and cancer pancreatic tissue samples is significant, P < 0.05). 
correlation coefficient analysis (Fig. 2J). The value of 
Pearson product-moment correlation coefficient (R) was  
equal to 0.90 with P values less than 0.05, suggesting 
a highly linear correlation between Plk1 protein expres-
sion and tumor volume. We also compared protein 
expression level of Plk1 between control untreated 
tumors and gemcitabine-treated tumors. Three untreat-
ed control tumors all showed high levels of Plk1 expres-
sion; while the gemcitabine-sensitive tumors tended 
to have lower levels of Plk1, the gemcitabine-resistant 
tumors retained high levels of Plk1 (Fig. 2K). The 
decrease of Plk1 levels can be because of individual 
host–tumor interaction or the heterogeneity of cultur-
ed cancer cells, but either case supports a role of high 
levels Plk1 in maintaining gemcitabine resistance. 
These results are consistent with our observations in 
the cell-based experiments, providing additional evi-
dence to support a functional correlation between Plk1 
protein expression and gemcitabine resistance in pan-
creatic cancer. 
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Figure 2. Plk1 expression correlates 
with gemcitabine resistance in cells 
and in vivo. A, HPDE6, BxPC-3, and 
Panc-1 cells were synchronized by 
thymidine (24 hours) or nocodazole 
(10 hours) treatment, then whole-
cell lysates were extracted and 
analyzed by anti-Plk1 and anti-
b-actin Western blots. B, Panc-1 
cells were treated with gemcitabine 
(100 nmol/L), BI2536 (1 nmol/L), 
or both for 72 hours, followed 
by Western blotting. C, structure 
of BI2536. D, structure of 
gemcitabine. E, HPDE6 cells 
were infected with lentivirus to 
overexpress Plk1. Twelve hours 
after infection, cells were 
treated with gemcitabine (50 or 
200 nmol/L) for 24 hours and 
harvested for Western blotting. 
F, Panc-1-derived xenograft 
tumors from nude mice that had 
been treated with gemcitabine 
(40 mg/kg) twice a week for 
8 weeks. G, volumes of tumors in F. 
H, weights of tumors in F. I, proteins 
were extracted from the tumors as 
in F and analyzed by Western blots. 
J, the correlational efficiency 
between Plk1 expression signal 
intensity in I and tumor volume is 
measured by Pearson product-
moment correlation coefficient 
analysis (R, 0.90; P < 0.05). K, 
proteins were extracted from 
gemcitabine-treated or -untreated 
Panc-1-derived xenograft tumors 
and analyzed by Western blots. 
Inhibition of Plk1 sensitizes pancreatic tumors to 
gemcitabine treatment in vivo 
To test if elevated Plk1-associated kinase activity 
in pancreatic cancer contributes to induction of gemcit-
abine resistance in vivo, we next examined the  effects  
of gemcitabine and BI2536, alone or in combination, 
on subcutaneous pancreatic tumors. As indicated in 
Fig. 3A, neither treatment with gemcitabine alone nor 
BI2536 alone significantly prevented tumor growth, 
likely due to the relatively low concentrations of the 
drugs used in this study. In striking contrast, a combi-
nation  of the same doses  of gemcitabine and  BI2536  
strongly inhibited tumor growth, suggesting that inhi-
bition of Plk1 sensitizes pancreatic tumors to gemcita-
bine treatment. 
Apoptosis and cell proliferation were further exam-
ined by TUNEL and Ki-67 staining on tumor sections 
prepared from these xenograft tumors by the end of 
the study. As shown in Fig. 3B, the combination of 
gemcitabine and BI2536 significantly increased cell 
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Table 1. The IC50 values of gemcitabine and 
BI2536 in Panc-1-cells 
Drugs IC50 (nmol/L) Notes 
BI2536 3.68 
Gemcitabine 1,284.07 
Gemcitabine (in 44.35 Combination 
combination with index ¼ 0.3 
2 nmol/L BI2536 
death compared with control or monotherapy groups. 
Although control tumors showed moderately faster cell 
proliferation, the 4 groups of tumors did not have a 
statistically significant different rate of cell proliferation 
as shown by Ki67 staining (Fig. 3C). These data suggest 
inhibition of Plk1 enhances the efficacy of gemcitabine 
mainly by promoting cell death. 
Figure 3. Inhibition of Plk1 sensitizes xenograft tumors to gemcitabine 
treatment. A, Panc-1 cells (5 106) were inoculated into flanks of female 
nude mice. One week after inoculation, the mice were treated with 
gemcitabine (40 mg/kg), BI2536 (15 mg/kg), or a combination of both 
drugs, and the relative sizes of the tumors in each group were plotted 
against the number of days (P < 0.01). B, in situ TUNEL assay of the 
xenograft tumors. The average percentages of TUNEL-positive cells from 
multiple tumor sections were calculated to assess the degree of cell 
death (P < 0.05). C, immunohistochemistry staining of Ki-67 of xenograft 
tumors. The average percentages of Ki-67-positive cells from multiple 
tumor sections were calculated to assess cell proliferation. 
Inhibition of Plk1 counteracts gemcitabine resistance 
in cells 
To confirm that Plk1 confers gemcitabine resistance in 
pancreatic cancer, we isolated tumor cells from Panc-1-
derived xenograft tumors with different resistance levels 
to gemcitabine (Supplementary Fig. S2A–D). Fourteen 
tumors were used to generate the sublines, 8 sublines 
were generated. As shown in Fig. 4A, consistent with our 
previous observations, the gemcitabine-sensitive tumors 
(#6) had a lower level of Plk1. Interestingly, the p-Orc2 
level increased 3-fold for tumor #19 compared with tumor 
#6, and increased by 4-fold for tumor #21 compared with 
tumor #6, which correlated with the high expression of 
Plk1 (Fig. 4A). In vitro measurement of the gemcitabine 
IC50 values of these tumor cells further confirmed their 
gemcitabine resistance (Fig. 4B). Cells derived from 
tumors 19 and 21 had higher gemcitabine IC50 values in 
vitro corresponding to their larger tumor sizes in vivo. 
Because of these elevated Plk1 levels and higher gemci-
tabine IC50 values, we further treated those gemcitabine-
resistant tumor cells with gemcitabine in vitro, alone or in 
combination with BI2536. Both gemcitabine-resistant 
tumor cells became more gemcitabine sensitive in the 
presence of a low dosage of BI2536 (Fig. 4C, 4D), while 
the same dosage of BI2536 alone did not significantly 
affect the cell viability (Supplementary Fig. S2 E and F). 
Finally, we further confirmed that the gemcitabine-resis-
tant tumor cells are more sensitive to inhibition of Plk1 on 
the basis of the more rapid response of these cells to BI2536 
treatment as measured by pH3 staining (Histone H3 is 
specifically phosphorylated at Ser10 during mitosis, 
which can serve as a mitotic marker) and FACS analysis 
(Supplementary Fig. S2G and H). These analyses support 
the notion that Plk1 confers the gemcitabine resistance of 
pancreatic cancer. 
Plk1 phosphorylation of Orc2 promotes DNA 
replication in the presence of gemcitabine 
Next, we dissected the mechanism for Plk1-associated 
gemcitabine resistance in pancreatic cancer. Orc2 is a key 
component of the pre-RC complex, which plays important 
roles in initiation of DNA replication (19). We recently 
reported that Plk1 phosphorylation of Orc2 promotes 
DNA replication under various stress conditions (16). 
Because gemcitabine-resistant pancreatic tumors have 
elevated Orc2 phosphorylation, we hypothesize that Plk1 
phosphorylation of Orc2 is a driving force for cell prolif-
eration in the presence of gemcitabine in pancreatic 
cancer. 
We first asked whether Plk1-mediated Orc2 phosphor-
ylation is enhanced at the replication origin by the DNA 
replication stress inducedbygemcitabine.Toward this end, 
we conducted ChIP experiments with antibodies against 
Orc2 and p-Orc2, and examined the well-defined Orc2-
associated DNA replication origin (MCM4). As shown 
in Fig. 5A, we were able to detect the signal by Orc2 
antibody on the MCM4 origin ( 500 genomic units) and 
the signal by phospho-Orc2 antibody ( 200 genomic units) 
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Figure 4. Inhibition of Plk1 
counteracts the gemcitabine 
resistance in cells derived from 
gemcitabine-resistant tumors. 
A, Panc-1-derived xenograft 
tumors were treated as in Fig. 3A 
to generate tumors with different 
sensitivities to gemcitabine. Part of 
each tumor sample was subjected 
to protein extraction for Western 
blots. B, cells isolated from the 
tumors as in A were grown in 
96-well plates and cell viability 
was assessed. C and D, isolated 
gemcitabine-resistant cells (#19 
and #20) were grown in 96-well 
plates, treated with gemcitabine 
alone or in combination with 
BI2536, and cell viability was 
assessed (P < 0.05). 
in control cells without gemcitabine treatment. After gem-
citabine treatment, the signal by Orc2 antibody remained 
about the same, but the signal by the p-Orc2 antibody 
increased to approximately 450 genomic units, an approx-
imately 2-fold increase compared with untreated cells (Fig. 
5A). This observation supports our hypothesis that Plk1-
mediated phosphorylation of Orc2 at the replication origin 
is elevated in response to gemcitabine treatment. 
To further evaluate the significance of this phosphory-
lation event in resistance to gemcitabine in pancreatic 
cancer, Panc-1 cells expressing Orc2-WT or Orc2-A (Plk1 
unphosphorylatable mutant, S188A) were treated with 
gemcitabine and subjected to BrdU labeling assays (Sup-
plementary Fig. S3A). Without gemcitabine treatment, 
Orc2-WT and Orc2-A cells displayed similar incorpo-
ration of BrdU. However, Orc2-A-expressing cells 
showed reduced DNA replication compared with Orc2-
WT cells upon gemcitabine treatment (Fig. 5B). This result 
suggests that Panc-1 cells expressing the Orc2-A mutant 
are more sensitive to gemcitabine treatment, indicating 
that Plk1 phosphorylation of Orc2 maintains DNA repli-
cation capacity in the presence of gemcitabine. Treating 
Panc-1 cells with BI2536 also decreases p-Orc2 level (Sup-
plementary Fig. S1B). To further confirm this notion, we 
examined cell death in these two populations upon gem-
citabine treatment. Cells expressing the Orc2-A mutant 
showed increased cell death compared with cells expres-
sing Orc2-WT, suggesting that Plk1 phosphorylation of 
Orc2 is, indeed, one mechanism for increased gemcitabine 
resistance in pancreatic cancer (Fig. 5C). 
Plk1 phosphorylation of Hbo1 increases cFos, 
consequently elevating its target, MDR1 
Hbo1, the enzyme responsible for histone H4 acety-
lation, is a core subunit of a protein complex comprised 
of JADE1/2/3 paralogs, hEaf6 and ING5. This complex 
interacts with the Mcm helicase and is essential for 
DNA replication to occur during S phase (20). Recently, 
it was reported that Hbo1 is recruited to the promoter 
of AP-1 and serves as a coactivator to increase AP-1 
transcription in response to environmental stress (21). 
More importantly, the expression level of Hbo1 is 
high in various human carcinomas (22). Previous stud-
ies in our laboratory showed that Plk1 phosphorylation 
of Hbo1 positively regulates its acetylation activity 
to promote DNA replication (17). Given these facts, 
we next asked whether Plk1 phosphorylation of Hbo1 
also contributes to gemcitabine resistance in pancreatic 
cancer. 
To test this hypothesis, we first conducted BrdU-label-
ing assays with cells expressing Hbo1-WT or Hbo1-A 
mutant (Plk1 unphosphorylatable mutant, S57A; Supple-
mentary Fig. S3B). As shown in Supplementary Fig. S3C, 
cells expressing Hbo1-A are more sensitive to gemcitabine 
treatment as compared with cells expressing Hbo1-WT. 
As a result of this sensitivity, cells expressing Hbo1-A 
showed increased cell death as indicated by an increased 
cleaved-PARP protein level after gemcitabine treatment 
(Supplementary Fig. S3D). These data suggest that Plk1 
phosphorylation of Hbo1 also plays a role in gemcitabine 
resistance of pancreatic cancer. 
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Figure 5. Plk1 phosphorylation of 
Orc2 promotes DNA replication in 
the presence of gemcitabine. A,  
Panc-1 cells were treated with 
gemcitabine (50 mmol/L) for 12 
hours and then subjected to ChIP 
analysis. The qRT-PCR was carried 
out with DNA that was extracted 
from chromatin precipitated with 
antibodies against Orc2 or p-Orc2. 
The MCM4 locus represents an 
established replication origin (29). 
In6 is the region 6-kb upstream of 
the MCM4 locus, and Ex9 is the 
region 5-kb downstream of the 
MCM4 locus. B, Panc-1 cells were 
transfected with Orc2-WT 
or Orc2-A constructs and 
synchronized by a double 
thymidine block (DTB, 16-hour 
thymidine block, 8 hours of release, 
followed by a second thymidine 
block for 16 hours) protocol. After 
release from the second thymidine 
block, cells were treated with 
gemcitabine (50 or 200 nmol/L) for 
24 hours, followed by BrdU labeling 
assay. C, whole-cell lysates from 
Panc-1 cells treated as in B were 
subjected to Western blots. 
To dissect the mechanism of this observation, we first 
examined the occupancy of endogenous Hbo1 at the 
replication origin upon gemcitabine treatment by ChIP 
analysis. To our surprise, Hbo1 was significantly 
decreased from the replication origin after gemcitabine 
treatment (Supplementary Fig. S3E). Instead, we observed 
that Hbo1 accumulated at the promoter of cFos (Fig. 6A), 
an AP-1 transcription factor. This observation is consistent 
with the previous report that Hbo1 is recruited at the cFos 
promoter site to serve as a transcriptional coactivator 
upon stress (21). Therefore, it is possible that Hbo1 at the 
cFos promoter activates cFos gene transcription. As the 
induction of cFos by therapeutic drug treatment is 
involved in the acquisition of drug resistance (23–25), we 
then examined whether cFos transcription is induced by 
gemcitabine treatment. As shown in Fig. 6B, the expres-
sion level of cFos was increased by 2.5-fold after 1-hour 
gemcitabine treatment. Further, overexpression of Hbo1-
WT, but not Hbo1-A, significantly amplified the induction 
of cFos (20-fold) on gemcitabine treatment (Fig. 6C), 
suggesting phosphorylation of Hbo1 contributes to the 
induction of cFos by gemcitabine treatment. 
To test whether the elevated cFos contributes to gemci-
tabine resistance in pancreatic cancer, we next examined 
its transcriptional target, MDR1, as MDR1 has been 
reported to mediate drug resistance by exporting drugs 
out of cells (24, 26, 27). Consistent with the results in Fig. 
6C, we observed that overexpression of Hbo1-WT, but not 
Hbo1-A, also amplified the induction of MDR1 (3-fold) 
upon gemcitabine treatment (Fig. 6D). Moreover, the 
expression levels of cFos and MDR1 were higher in 
gemcitabine-resistant cells than in gemcitabine-sensitive 
cells (Fig. 6E and F), suggesting a possible role of the cFos-
MDR1 pathway in gemcitabine resistance. To confirm the 
contribution of Plk1 phosphorylation of Hbo1 on the 
elevation of cFos and MDR1, we treated the gemcita-
bine-resistant cells with BI2536 and examined the expres-
sion of cFos and MDR1. As shown in Fig. 6G and H, 
inhibition of Plk1 decreased cFos expression by 50% and 
MDR1 expression by 40%, confirming the role of Plk1 
phosphorylation of Hbo1 on the elevation of cFos and 
MDR1 levels. Finally, to test whether elevated expressions 
of cFos and MDR1 confer gemcitabine resistance, we 
employed RNAi to knock down their expression in gem-
citabine-resistant cells (Supplementary Fig. S4), and 
found that the IC50 of gemcitabine was reduced from 
171.2 to 14.9 mmol/L after cFos RNAi transfection and to 
1.0 mmol/L after MDR1 RNAi transfection (Fig. 6I). These 
data suggest that elevated cFos and MDR1 maintain the 
gemcitabine resistance in pancreatic cancer. 
Finally, to test the contribution of these two phosphor-
ylation events to gemcitabine resistance, Panc-1 cells 
were synchronized, transfected, and treated with or 
without gemcitabine. As shown in Fig. 6J, Panc-1 cells 
expressing Hbo1-A alone showed less cleaved-PARP 
protein level than cells expressing both Hbo1-A and 
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Figure 6. Plk1 phosphorylation of Hbo1 increases cFos expression and consequently elevates its target, MDR1. A, Panc-1 cells were treated with gemcitabine 
(50 mmol/L) for 12 hours and then subjected to ChIP analysis with anti-Hbo1 antibody. qRT-PCR was carried out with DNA extracted from precipitated 
chromatin to examine the association of Hbo1 on the promoters of cFos and Sat2 (P < 0.05). Hbo1 localization on the promoter of Sat2 is not induced by 
stress and, thus, serves as a negative control for this experiment (#21). B, Panc-1 cells were treated with gemcitabine and harvested at different times 
after treatment. The mRNA level of cFos from each sample was quantified by qRT-PCR and normalized to a mock control. C and D, Panc-1 cells were 
transfected with Flag-Hbo1-WT, Flag-Hbo1-S57A, or Flag vector alone, treated with gemcitabine, and harvested at different times after treatment. The 
mRNA level of cFos (C) and MDR1 (D) for each sample was examined by qRT-PCR (P < 0.05). The mRNA levels of cFos (E) and MDR1 (F) in the 
gemcitabine-sensitive Panc-1 cell line (#6) and gemcitabine-resistant Panc-1 cell lines (#19 and #21) were examined by qRT-PCR. G and H, after 
gemcitabine-resistant Panc-1 cells (#19 and #21) were treated with BI2536 (500 nmol/L) for 4 hours, the mRNA levels of cFos (G) and MDR1 (H) were examined 
by qRT-PCR (P < 0.05). I, gemcitabine-resistant Panc-1 cells (#19) were transfected with cFos or MDR1 siRNA for 24 hours and the IC50 values of 
gemcitabine were determined. J, Panc-1 cells were synchronized by double thymidine block protocol, then transfected with Flag-Hbo1-A, GFP-Orc2-A, 
or both, then treated with or without gemcitabine (50 nmol/L) for 24 hours, and subjected to Western blot analysis. 
Orc2-A mutants in response to gemcitabine treatment. mutants. This result suggests that Plk1 phosphorylation 
Cells expressing Orc2-A alone has a similar cleaved- of Orc2 might be a dominant mechanism for Plk1-medi-
PARP protein expression level as cells expressing both ated gemcitabine resistance. 
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Discussion 
Gemcitabine is the current standard chemotherapy for 
pancreatic cancer, a deadly disease. However, only 30% of 
patients benefit from this agent, and among those, almost 
all will become resistant, usually within 3 to 4 months. In 
this study, we have investigated the putative mechanisms 
of gemcitabine resistance in pancreatic tumors. We found 
that Plk1 phosphorylation of Orc2 and Hbo1 mediates 
gemcitabine resistance and that inhibition of Plk1 sensi-
tizes pancreatic tumor cells to gemcitabine treatment in 
vitro and in vivo. Plk1 blockade may represent a novel 
avenue for treatment of gemcitabine-resistant pancreatic 
cancer. 
Plk1 is a well-established regulator of many mitosis-
related events. However, our recent work suggests that 
Plk1 might also have functions in interphase events, such 
as DNA replication. For example, we showed the involve-
ment of Plk1 in promotion of DNA synthesis by phos-
phorylation of Orc2 under replication stress. Moreover, 
elevated levels of Plk1 and phoshpho-Orc2 in pancreatic 
tumors are correlated with gemcitabine resistance (Figs. 2 
and 3). Increased phosphorylation of Orc2 at the replica-
tion origin on gemcitabine treatment maintains DNA 
replication for cell survival (Fig. 5A and B). As a conse-
quence, pancreatic cancer cells expressing the Plk1-
unphosphorylatable mutant of Orc2 became more sensi-
tive to gemcitabine treatment (Fig. 5C), suggesting that 
Plk1-mediated phosphorylation of Orc2 is one mecha-
nism that contributes to gemcitabine resistance of pan-
creatic cancer. 
We acknowledge that Plk1 likely regulates cellular 
responses to gemcitabine treatment via multiple mechan-
isms. We also reported previously that Hbo1 is phosphor-
ylated by Plk1 to regulate DNA replication (17). To our 
surprise, we observed a decrease of Hbo1 at the replica-
tion origin upon gemcitabine treatment (Supplementary 
Fig. S3E). Instead, Hbo1 accumulated at the promoter 
region of cFos, an AP-1 transcription factor (Fig. 6A), 
which is consistent with the recent report of Hbo1 recruit-
ment to the AP-1 promoter under environmental stress 
and the overall role of Hbo1 in regulating the p53 pathway 
(21, 28). These observations suggest that Hbo1 might 
contribute to gemcitabine resistance independent of its 
role in DNA replication. To support this notion, we found 
that cFos and its target MDR1 were significantly induced 
by gemcitabine treatment in a manner dependent on Plk1 
phosphorylation of Hbo1 (Fig. 6B–D). The elevation of 
cFos transcription is likely due to the accumulation of 
Hbo1 at the cFos promoter on gemcitabine treatment (Fig. 
6A). In the gemcitabine-resistant Panc-1 cells that we 
isolated from xenograft tumors, both cFos and MDR1 
expression were elevated (Fig. 6E, F). Significantly, knock-
down of cFos or MDR1 sensitizes these gemcitabine-
resistant cells to gemcitabine treatment. Additional genes 
in the p53 pathway that are regulated by Hbo1 may also 
have a role in gemcitabine resistance, but our data support 
one mechanism of Hbo1-mediated resistance in which 
overexpressed Plk1 in pancreatic tumors phosphorylates 
Hbo1 to elevate cFos and its target MDR1, eventually 
contributing to gemcitabine resistance. 
Combining these results with the data of Orc2 described 
above, we propose a model that Plk1 phosphorylates Orc2 
and Hbo1 to mediate gemcitabine resistance in pancreatic 
cancer. As shown in Fig. 3, inhibition of Plk1 kinase 
activity significantly enhanced gemcitabine sensitivity in 
pancreatic cancer. Gemcitabine treatment alone did not 
significantly increase cell death or block cell proliferation 
in the Panc-1 cell-based xenograft study, mirroring gem-
citabine resistance found in the clinical setting. However, 
inhibition of Plk1 in combination with gemcitabine sig-
nificantly increased cell death and prevented tumor 
growth, indicating that Plk1 activity is critical for the 
development of resistance to gemcitabine. Overexpres-
sion of Plk1 in HPDE6 cells, which are sensitive to gem-
citabine treatment (Supplementary Table S1), induced 
resistance of HPDE6 cells to gemcitabine (Fig. 2E). This 
result suggests a potential role of Plk1 in secondary 
resistance to gemcitabine. Further, we showed that 
tumors maintaining high Plk1 levels on gemcitabine treat-
ment were resistant to gemcitabine, and that tumors with 
decreased Plk1 levels on gemcitabine treatment were 
sensitive to gemcitabine (Fig. 2K), indicating that the 
response of Plk1 level on gemcitabine treatment can be 
used to predict the efficacy of gemcitabine in the treatment 
of pancreatic cancer. By examining a potential mechanism 
of gemcitabine resistance of pancreatic cancer, our study 
provides a novel rationale for molecularly targeting Plk1 
in the treatment of this deadly disease. 
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